Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-116872
Filing Date
2024-10-24
Accepted
2024-10-24 09:15:20
Documents
93
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q alks-20240930.htm   iXBRL 10-Q 2756337
2 EX-31.1 alks-ex31_1.htm EX-31.1 17069
3 EX-31.2 alks-ex31_2.htm EX-31.2 17084
4 EX-32.1 alks-ex32_1.htm EX-32.1 19469
5 GRAPHIC img77523168_0.jpg GRAPHIC 4907
6 GRAPHIC img77523168_1.jpg GRAPHIC 134869
7 GRAPHIC img77523168_2.jpg GRAPHIC 43283
8 GRAPHIC img77523168_3.jpg GRAPHIC 21082
  Complete submission text file 0000950170-24-116872.txt   11706761

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alks-20240930.xsd EX-101.SCH 1476828
96 EXTRACTED XBRL INSTANCE DOCUMENT alks-20240930_htm.xml XML 2212302
Mailing Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000
Business Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000 00-353-1-772-8000
Alkermes plc. (Filer) CIK: 0001520262 (see all company filings)

EIN.: 981007018 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35299 | Film No.: 241390895
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)